Abstract
Mpox is a zoonotic viral disease caused by the monkeypox virus (MPXV). Human cases have been mainly restricted to the African continent until the worldwide multi-country outbreak unfolded in 2022. We reconstructed epidemiological links of MPXV infections using genomic epidemiology in Rio Grande do Sul State, southern Brazil, during 2022 and 2023. We detected five well-supported clades, three representing local transmission chains that were mostly restricted to the 2022 virus spread, one supported year-long maintenance encompassing samples from 2022 and 2023, and one new importation from Europe in 2023. Our results provide new insights into the geographic extent of community transmission and its association with viral diversity during the more pronounced 2022 mpox upsurge and during the following lower incidence endemic transmission phase. These findings highlight the power of continued genomic surveillance to uncover hidden transmission chains to understand viral dynamics and inform public health responses. The detection of sustained endemic transmission in the state is important to guide targeted control measures to curtail further community and international transmission and highlight the need for strengthening genomic surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS/MS/CNPq 08/2020-PPSUS, Grant process 21/2551-0000059-7, FAPERGS/FIOCRUZ 13/2022 - REDE SAUDE-RS, grant process 23/2551-0000510-7 and FAPERGS 14/2022 - ARD/ARC, grant process 23/2551-0000852-1). Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) and Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul has provided a fellowship to R.S.S (FAPERGS/CNPq 07/2022) and a productivity grant PQ1D to GLW (307209/2023-7). ABGV holds a Research Fellowship (PQ2) from CNPq (Grant process 304476/2022-6).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the Research Ethics Committee (CEP) at Escola de Saude Publica (SES-RS). Process number: CAAE: 67181123.1.0000.5312.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
